NGM Biopharmaceuticals

In a refreshingly transparent disclosure, NGM Bio CEO reveals what led to 33% head count reduction
In a refreshingly transparent disclosure, NGM Bio CEO reveals what led to 33% head count reduction
Fierce Biotech
NGM Biopharmaceuticals
solid tumors
layoffs
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
Flag link:
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
Fierce Biotech
NGM Biopharmaceuticals
NASH
clinical trials
Flag link:
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
Xconomy
NGM Biopharmaceuticals
NASH
clinical trials
aldafermin
Flag link:
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Yahoo/Zacks.com
earnings
biotech
Eyenovia
SAGE Therapeutics
AC Immune
Ascendis
NGM Biopharmaceuticals
Flag link:
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
Fierce Biotech
NGM Biopharmaceuticals
NASH
clinical trials
FGF19 aldafermin
Flag link:
Back to business for biotech flotations
Back to business for biotech flotations
EP Vantage
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing
NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing
Xconomy
NGM Biopharmaceuticals
IPOs
Merck
Flag link:
March Madness: "The Fabulous 5" Life Science IPOs
March Madness: "The Fabulous 5" Life Science IPOs
BioSpace
IPOs
Genfit
Silk Road Medical
NGM Biopharmaceuticals
Precision Biosciences
Shockwave Medical
Flag link:
NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million
NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million
CP Wire
NGM Biopharmaceuticals
IPOs
Merck
NASH
Flag link:
NGM Biopharmaceuticals Updates IPO Filing – Will Raise Over $122 Million
NGM Biopharmaceuticals
IPOs
Merck
NASH
Flag link:
Merck doubles down on NGM Bio pact but culls obesity drug
Merck doubles down on NGM Bio pact but culls obesity drug
Fierce Biotech
Merck
R&D
NGM Biopharmaceuticals
NP201
NASH
obesity
Flag link:
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Merck bags global rights to NGM NASH drug, plans phase 2b trial
Fierce Biotech
Merck
NASH
NGM Biopharmaceuticals
type 2 diabetes
clinical trials
MK-3655
Flag link:
NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH
NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH
CP Wire
NGM Biopharmaceuticals
NASH
NGM282
Flag link:
NGM Bio Releases Promising Results From Phase 2 Study Of NGM282 In NASH
NGM Biopharmaceuticals
NASH
NGM282
Flag link:
One Year Later: Whatever Happened to Those Biotech Companies?
One Year Later: Whatever Happened to Those Biotech Companies?
Forbes
Atlas Venture
Illumina
Adaptive Biotechnologies
NGM Biopharmaceuticals
Moderna
Flag link:
The 2015 Fierce 15 biotech execs take a bow
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics
Flag link:

Pages